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Background:  A continuous interscalene brachial plexus block is a highly effective postoperative analgesic modality 
after shoulder surgery.  However, there is no consensus regarding the optimal basal infusion rate of ropivacaine for 
a continuous interscalene brachial plexus block.  A prospective, double blind study was performed to compare two 
different basal rates of 0.2% ropivacaine for a continuous interscalene brachial plexus block after shoulder surgery.
Methods:  Sixty-two patients receiving shoulder surgery under an interscalene brachial plexus block were included.   
The continuous interscalene brachial plexus block was performed using a modified lateral technique with 30 ml of 
0.5% ropivacaine.  Surgery was carried out under an interscalene brachial plexus block or general anesthesia.  After 
surgery, the patients were divided randomly into two groups containing 32 each.  During the first 48 h after surgery, 
groups R8 and R6 received a continuous infusion of 0.2% ropivacaine at 8 ml/h and 6 ml/h, respectively.  The pain 
scores at rest and on movement, supplemental analgesia, motor block, adverse events and patient’s satisfaction were 
recorded. 
Results:  The pain scores, supplemental analgesia, motor block, adverse events and patient’s satisfaction were similar 
in the two groups.
Conclusions:  When providing continuous interscalene brachial plexus block after shoulder surgery, 0.2% 
ropivacaine at a basal rate of 8 ml/h or 6 ml/h produces similar clinical efficacy.  Therefore, decreasing the basal rate 
of CISB is more appropriate considering the toxicity of local anesthetics.  (Korean J Anesthesiol 2010; 59: 27-33)
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Introduction 
    Surgery in the shoulder region is often associated with severe 
postoperative pain that may require opioids for several days 
[1]. A single-shot interscalene brachial plexus block (ISB) can 
provide pain relief for up to 18 h, after which the patient is 
reliant on conventional analgesia with its associated side-effects. 
Compared to IV patient-controlled analgesia (PCA) for open 
shoulder surgery, prospective, randomized, controlled trials 
have demonstrated that the use of a continuous interscalene 
brachial plexus block (CISB) reduces the postoperative 
requirements for opioids and provides better analgesia, reduced 
opioid-related side effects, and better patient satisfaction for at 
least the first 48 h after surgery [1,2].
    Ropivacaine is a long-acting amide local anesthetic with a 
similar structure and clinical profile to bupivacaine but with 
less associated toxicity at comparable doses [3]. For this reason, 
ropivacaine is the preferred local anesthetic for peripheral 
nerve blocks and continuous peripheral nerve infusions in 
many institutions. A comparison of CISB with 0.2% ropivacaine 
versus 0.15% bupivacaine revealed equivalent analgesia in both 
groups but significantly less motor block with ropivacaine [4]. 
    However, there is no consensus regarding the optimal basal 
infusion rate of ropivacaine for CISB. As a result, many different 
basal infusion rates for CISB have been used. Ilfeld et al. [5] 
reported that providing patients with a ropivacaine (0.2%) CISB 
at 8 ml/h produced potent analgesia after moderate to severely 
painful shoulder surgery, whereas lower infusion rates were 
often inadequate. 
    At our institution, a regimen of 0.2% (2 mg/ml) ropivacaine 
at 6 ml/h, supplemented with on-demand 3 ml/20 min boluses 
are commonly used for CISB. Low background infusions are 
advantageous for CISB, in that they carry a potential risk of local 
anesthetic toxicity and enable longer potent analgesia provided 
by limited volume pumps.
    This prospective, double blind study examined the quality 
of postoperative analgesia, supplemental analgesia, motor 
block, adverse events and patient’s satisfaction of CISB with 
0.2% ropivacaine at a basal rate of either 8 ml/h or 6 ml/h for 
shoulder surgery.
Materials and Methods
    With ethics committee approval and written informed consent, 
64 ASA physical status I-III in-patients undergoing shoulder 
surgery with an interscalene brachial plexus block or general 
anesthesia were examined. The exclusion criteria were patients 
receiving chronic analgesic therapy, as well as patients with 
severe bronchopulmonary disease, neuropathy or an allergy to 
amide local anesthetics, nonsteroidal anti-inflammatory drugs 
or opioids. 
    Before the block procedure, standard monitors were placed 
and the patients received 0.1 μg/kg of sufentanil intravenously. 
All nerve blocks were performed by, or under the supervision 
of, an experienced anesthesiologist. The ISB was performed in 
all patients through a catheter using modified lateral techniques 
before sedation or the induction of general anesthesia. 
Anatomical surface landmarks of the neck were identified and 
marked with a surgical marking pen. Formal sterile techniques 
were used. The interscalene brachial plexus was identified 
using a nerve stimulator (Stimuplex
Ⓡ-DIG, B/Braun, Germany) 
connected to the proximal end of the metal inner needle of a 
plastic cannula (Contiplex
Ⓡ A, B/Braun, Germany). 
    The stimulation frequency was set to 1 Hz and a pulse 
duration of 0.1 ms, while the intensity of the stimulating current, 
which was initially set to 1 mA, was decreased progressively 
to ≤0.6 mA after the appropriate motor response had been 
observed. A 22-gauge catheter was introduced 4-5 cm into 
the plexus sheath through a cannula. All patients received 
local anesthetics through the catheter. 0.5% ropivacaine 30 ml 
were injected slowly in 5 ml aliquots with multiple negative 
aspirations of blood. The catheter was tunneled subcutaneously 
over 3-4 cm through an 18-gauge IV needle and fixed to the 
skin with a tight suture.
    Surgical anesthesia was defined as the complete loss of cold 
sensation at the skin dermatomes involved in the surgical 
field (from C5-6) and an inability to abduct the arm and flex 
the forearm against gravity at the shoulder and elbow joints, 
respectively. The block was considered to have failed if the block 
was not complete 45 min after the injection.
    The general anesthetic technique used (when necessary) was 
standard for all patients. After the block was complete, induction 
was performed with 3 μg/ml propofol (Fresofol
Ⓡ 2%, Fresenius 
Kabi, Germany) using a target-controlled infusion (TCI) system 
(Orchestra Base Primea
Ⓡ, Fresenius Vial, France). At the same 
time, sufentanil was started using the same TCI system used for 
propofol. Propofol at an effect site concentration of 3 μg/ml and 
0.1 ng/ml sufentanil were administered. Tracheal intubation 
was facilitated using 0.6 mg/kg rocuronium administered within 
3 min before tracheal intubation. Anesthesia was maintained 
with propofol 2-3 μg/ml, sufentanil 0.1 ng/ml. Those not under 
general anesthesia received sufentanil 0.2-0.3 μg/kg IV and a 
propofol infusion at 50 μg/kg/min for sedation. Supplemental 
oxygen was administered throughout the procedure at 6 L/min 
through a mask.
    In the postanesthetic care unit (PACU), the patients were 
divided randomly into two groups containing 32 each. During 
the first 48 h postoperatively, Group R8 received a continuous 
infusion of 0.2% ropivacaine at 8 ml/h plus boluses of 3 ml with 
a lockout time of 20 min through the interscalene catheter using 29 www.ekja.org
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a portable battery-powered pump (Accumate
Ⓡ 1000, Wooyoung 
Medical, Korea). Group R6 received a continuous infusion of 
the same solution at 6 ml/h plus boluses of 3 ml with a lockout 
time of 20 min. In addition, rescue analgesia with 60 mg of 
IM diclofenac was available on demand. The demographic 
parameters, type and duration of the surgical procedure were 
similar in the two groups (Table 1 and 2).
    Pain at rest and on movement, as well as the motor function 
of the operated arm was assessed at the PACU and at 24 and 
48 h after surgery. The pain intensity was assessed using a 10-
cm visual analog scale (0 cm = no pain; 10 cm = worst pain 
imaginable) for pain at rest and during passive movement 
(90
o abduction) of the shoulder. The motor function of the 
operated arm was evaluated by asking the patient to squeeze 
the hands of a blinded observer with both hands, who scored 
the motor function using a three-point scale as follows: 0 = no 
motor block, similar strength in both hands; 1 = partial motor 
block, operated hand weaker than the non-operated one; 2 = 
complete motor block, unable to squeeze with the operated 
hand. Supplemental analgesia, ropivacaine consumption, 
sleep disturbance, adverse events, and satisfaction score (1 = 
satisfied; if needed will undergo the same procedure again in 
the future; 2 = unsatisfied; if needed in the future, will ask for a 
different analgesia technique.) were recorded at the end of the 
study period. All data was collected by an anesthesiologist who 
was neither involved in the administration of anesthesia nor in 
the patient care in the recovery room.
    Using type I (α) and type II (β) errors of 0.05 and 0.2 
respectively, and considering a 20% difference in the average 
pain scores over a 48 hour period between the groups to be the 
minimum relevant difference, it was calculated that a sample of 
25 patients per group would be necessary. Seven more patients 
per group were added to increase the power.
    Statistical analysis was performed using Microsoft Excel 
Version 2007 (Microsoft Office Excel
Ⓡ, Microsoft, USA). The 
normal distribution of the data was first evaluated using a 
Kolmogorov-Smirnov test. The normally distributed variables 
were analyzed using parametric methods. The data is reported 
as the mean ± SD, and the groups were compared using a 
Student’s t-test. Otherwise, the variables were analyzed using 
nonparametric methods. The groups were summarized 
using the median (10
th-90
th percentiles) and the groups were 
compared using a Mann-Whitney rank-sum test. A Fisher’s 
exact test was used to compare the categorical data where 
appropriate. A P value < 0.05 was considered significant. 
Results
    62 patients enrolled completed the study. One patient in 
group R6 was excluded because no motor response could be 
elicited. One patient in group R8 was excluded due to chest 
discomfort caused by phrenic nerve paresis. In one patient in 
group R8 and two patients in group R6, the interscalene catheter 
was accidentally pulled out 24hrs after surgery. Statistical 
analyses were performed without these patients at the missing 
time points. Two patients in group R8 and one in group R6 
underwent surgery with general anesthesia. Table 3 lists the 
elicited motor responses. 
    Fig. 1 and 2 show the VAS scores at rest and on shoulder 
abduction . The pain scores in the PACU at 24 and 48 h after 
surgery were similar in the two groups. In addition, the 
proportion of patients requiring rescue diclofenac analgesia 
Table 1. Demographic Data
Group R8 (n = 31) Group R6 (n = 31)
Age (years)
Male/female
Height (cm)
Weight (kg)
ASA physical status (I/II/III)
Duration of surgery (min)
54 ± 16
20/11
163 ± 9
64 ± 10
12/18/1
140 ± 44
55 ± 15
18/13
162 ± 10
63 ± 10
11/19/1
138 ± 59
Values are the mean ± SD. Group R8: continuous interscalene 
brachial plexus block with 0.2% ropivacaine at a rate of 8 ml/h, 
Group R6: continuous interscalene brachial plexus block with 0.2% 
ropivacaine at a rate of 6 ml/h.
Table 2. Surgical Procedures
Group R8 (n = 31) Group R6 (n = 31)
A/S RCR
A/S capsuloplasty
A/S debridement
Open RCR
SA
ACJ reconstruction
Osteosynthesis
10 (32)
  5 (16)
2 (6)
2 (6)
  4 (13)
2 (6)
  6 (19)
11 (35)
  4 (13)
  4 (13)
1 (3)
1 (3)
2 (6)
  8 (26)
Values are the number of patients (%). Group R8: continuous 
interscalene brachial plexus block with 0.2% ropivacaine at a rate of 8 
ml/h, Group R6: continuous interscalene brachial plexus block with 
0.2% ropivacaine at a rate of 6 ml/h. A/S: arthroscopic, RCR: rotator 
cuff repair, SA: shoulder arthroplasty, ACJ: acromioclavicular joint. 
Table 3. Motor Response to Nerve Stimulation 
   Group R8 (n = 30) Group R6 (n = 31)
Deltoid muscle
Triceps muscle
Biceps muscle
Pectoralis major muscle
13 (43)
   5 (17)
   6 (20)
   6 (20)
19 (61)
  5 (16)
  4 (13)
  3 (10)
Values are the number of patients (%). Group R8: continuous 
interscalene brachial plexus block with 0.2% ropivacaine at a rate 
of 8 ml/h, Group R6: continuous interscalene brachial plexus block 
with 0.2% ropivacaine at a rate of 6 ml/h.30 www.ekja.org
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was also similar in the two groups (Table 4). There were no 
significant differences in sleep disturbances on postoperative 
days 0 and 1 (Table 4). The volume of the local anesthetic 
solution administered at 24 h and 48 h postoperatively was 204 
± 18 and 404 ± 31 ml in group R8 and 152 ± 11 and 307 ±19 ml in 
group R6, respectively (Fig. 3). 
    Fig. 4 shows the progression of the motor block in the 
operated limb during the study period. There were no 
significant differences in motor block between the two groups.
Fig. 1. Median and range for the visual analog scale pain scores at 
rest (0 mm = no pain to 10 mm = worst pain imaginable). Group R8: 
continuous interscalene brachial plexus block with 0.2% ropivacaine 
at a rate of 8 ml/h, Group R6: continuous interscalene brachial plexus 
block with 0.2% ropivacaine at a rate of 6 ml/h. PACU: postanesthetic 
care unit.
Fig. 2. Median and range for the visual analog scale pain scores 
during passive movement of the shoulder (0 cm = no pain to 10 cm = 
worst pain imaginable). Group R8: continuous interscalene brachial 
plexus block with 0.2% ropivacaine at a rate of 8 ml/h, Group R6: 
continuous interscalene brachial plexus block with 0.2% ropivacaine 
at a rate of 6 ml/h. PACU: postanesthetic care unit.
Table 4. Analgesic Effectiveness
Group R8 (n = 31) Group R6 (n = 31)
Rescue analgesia 
  (with IM diclofenac)
    POD 
    POD 1
Sleep disturbance
    POD 
    POD 1
14 (45)
11 (35)
13 (42)
  6 (19)
14 (45)
10 (32)
10 (32)
  6 (19)
Values are the number of patients (%). Group R8: continuous 
interscalene brachial plexus block with 0.2% ropivacaine at a rate 
of 8 ml/h, Group R6: continuous interscalene brachial plexus block 
with 0.2% ropivacaine at a rate of 6 ml/h. POD: postoperative day.
Fig. 3. Local anesthetic consumption. Group R8: continuous 
interscalene brachial plexus block with 0.2% ropivacaine at a rate 
of 8 ml/h, Group R6: continuous interscalene brachial plexus block 
with 0.2% ropivacaine at a rate of 6 ml/h. PACU: postanesthetic care 
unit.
Fig. 4. Progression of the motor block in the operated limb during 48 
h of CISB. Group R8: continuous interscalene brachial plexus block 
with 0.2% ropivacaine at a rate of 8 ml/h, Group R6: continuous 
interscalene brachial plexus block with 0.2% ropivacaine at a rate of 
6 ml/h.31 www.ekja.org
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    Table 5 summarizes the adverse events during the study. No 
statistical difference was observed between the two groups. 
These adverse events were observed mainly during the 
immediate postoperative period. 
    The patients were not examined specifically for any long-term 
neurologic complications. However, neurological complications 
were reported by the surgeons in two patients in Group R8. 
One patient reported paresthesia in the first two fingers for 3 
weeks, which resolved progressively. The other patient reported 
paresthesia in the areas of the musculocu-taneous and radial 
nerve for 4 weeks, which also resolved progressively.
    There were no significant differences in patient’s satisfaction 
between the groups (Table 6).
Discussion
    This study demonstrated that after shoulder surgery, different 
basal infusion rates of CISB provide similar postoperative 
analgesia, supplemental analgesic requirements, motor block, 
side effects and high patient satisfaction during the infusion 
period. 
    Shoulder surgery is associated with severe postoperative 
pain. The options available to optimize postoperative pain 
control after shoulder surgery include IV PCA, intraarticular 
injection, suprascapular nerve block (SSNB), single-shot ISB 
and CISB. An SSNB is superior to an intra-articular injection 
after shoulder arthroscopy but is inferior to ISB [6]. ISB is 
superior to a subacromial bursa block [7]. In particular, CISB 
consistently provides superior analgesia with fewer side effects 
than either continuous subacromial infusion [8] or single-shot 
ISB. In addition, it allows earlier hospital discharge and possibly 
improves rehabilitation after major surgery [9,10].
    However, this technique requires the administration of large 
volumes of local anesthesia with the potential risk of toxicity 
due to the accumulation of the drug after prolonged periods 
of infusion [11]. Singlelyn et al. [12] reported that reducing the 
background infusion of 0.125% bupivacaine by half (5 ml/h) 
is associated with the use of small sized (2.5 ml/30 min) PCA 
boluses, which provide excellent pain relief, no side effects, 
and a 36% decrease in local anesthetic consumption. For this 
reason, a technique consisting of a background infusion and 
PCA boluses was chosen. 
    There is little information regarding the optimal combination 
of the local anesthetic volume and concentration for CIBS when 
used for postoperative analgesia after shoulder surgery. In the 
absence of extensive data, the infusion settings for long-acting 
local anesthetics delivered to the brachial plexus include a basal 
rate of 5 to 10 ml/h, a bolus volume of 2 to 5 ml/h, and lockout 
duration of 20 to 60 min. Some studies have supported the 
administration of relatively high volumes (>5 ml/h) of dilute 
local anesthetics, consistent with the large surface area of the 
brachial plexus in this region [5]. 
    In this study, there was no difference between the groups 
with regard to the pain intensity. The pain scores at rest and 
on shoulder abduction were similar in the two groups in the 
recovery room, 24 and 48 h postoperatively. In addition, there 
were no differences in the proportion of patients requiring 
rescue analgesia and sleep disturbances due to pain between 
the groups. These results support the comparable pain relief 
between the groups. 
    One reason for the lack of differences in pain scores may be 
that the basal infusion volumes are too enough and may even 
work in catheters that are not located precisely at the nerves. To 
better determine the difference between a “well placed” and 
a “poorly placed” catheter, one should use smaller amounts of 
local anesthetics. Paqueron et al. [13] demonstrated that 2.7 ml 
of mepivacaine 1.5% is sufficient to block the sciatic nerve in 
50% of patients if the catheter tip is located precisely.
    Another possible explanation for this finding is that the 
catheters were not placed as intimately to the C5-6 roots/
superior trunk in both groups. Therefore, the basal infusion 
volumes were too small. Hence, larger volumes will be needed 
for adequate pain control in both groups.
    The relative importance of the local anesthetic concentration/ 
volume versus dose has significant clinical consequences 
given the wide range of local anesthetic concentrations used 
for perineural infusion [5,14,15]. Le et al. [16] reported that for 
CISB, a lower concentration of local anesthetic at a higher basal 
rate provided superior analgesia. Fredrickson et al. [17] reported 
that after major shoulder surgery, ropivacaine 0.2% at 2 ml/h 
Table 5. Adverse Events
Group R8 (n = 31) Group R6 (n = 31)
Nausea
Dyspnea
Hoarseness
Horner’s syndrome
  1 (0.03)
  4 (0.13)
  5 (0.16)
14 (0.45)
  3 (0.03)
  2 (0.06)
  2 (0.06)
14 (0.45)
Values are the number of patients (%). Group R8: continuous 
interscalene brachial plexus block with 0.2% ropivacaine at a rate 
of 8 ml/h, Group R6: continuous interscalene brachial plexus block 
with 0.2% ropivacaine at a rate of 6 ml/h.
Table 6. Patient’s Satisfaction
Group R8 (n = 28) Group R6 (n = 30)
Unsatisfied
Satisfied
  3 (11)
25 (89)
2 (7)
28 (93)
Values are the number of patients (%). Group R8: continuous 
interscalene brachial plexus block with 0.2% ropivacaine at a rate 
of 8 ml/h, Group R6: continuous interscalene brachial plexus block 
with 0.2% ropivacaine at a rate of 6 ml/h.32 www.ekja.org
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with on-demand 5 ml boluses administered via an ultrasound-
guided C5-6 root/superior trunk perineural catheter produced 
similar analgesia, but greater patient satisfaction compared to 
those administered ropivacaine 0.4%. On the other hand, Ilfeld 
et al. [18] reported that for continuous posterior lumbar plexus 
blocks, the local anesthetic concentration and volume do not 
affect the nerve block characteristics, suggesting that the local 
anesthetic dose (mass) is the primary determinant of perineural 
infusion effects. Although it is unlikely that there is a single 
optimal local anesthetic dose for all patients, there may be an 
optimal protocol for administering perineural local anesthetics 
(e.g., initial basal rate, bolus dose volume, lock-out duration, 
and subsequent adjustments). Future research should examine 
not only the optimal starting dose for various perineural 
catheter infusions but also the subsequent changes in dosing 
during the acute postoperative period.
    A better sensorimotor dissociation of ropivacaine would be 
well suited to orthopedics because it may facilitate rehabili-
tation and improve the patient’s well being. A smaller basal 
infusion was expected to be less likely to cause a motor block 
and facilitate rehabilitation. However, both groups showed 
similar degree of motor block. 
    Single-shot ISB is associated with ipsilateral hemidia  phrag-
matic paresis in all patients [19]. Patients undergoing CISB 
are also at risk of diaphragmatic paresis. During CISB, paresis 
can occur in as many as 75% of cases and often persists until 
the end of the infusion [20,21]. Yang et al. [22] reported a 
patient who developed atelectasis of the lung and pleural 
effusion manifesting as chest discomfort during CISB. The 
diaphragmatic function was not assessed specifically in this 
study, but 6 patients experienced mild dyspnea that was 
resolved after applying oxygen by a mask. However, 1 patient 
complained of moderate chest discomfort and dyspnea, which 
was resolved after discontinuing the infusion, and was excluded 
from the study. 
    In this study, two patients in group R8 reported new neuro-
logical symptoms after CISB, which were quite minor and 
resolved within 4 weeks. Perioperative nerve injury after upper 
extremity surgery may be the result of several contributing 
factors, either unrelated or related directly to the regional 
anesthetic technique. The unrelated risk factors include the 
patient and surgical issues. Regional anesthetic factors that may 
contribute directly to anesthesia-related nerve injury include 
mechanical trauma, ischemic injury, or chemical injury. 
Continuous catheter techniques raise concern regarding the 
potential neurotoxicity from repeated perineural injections 
of local anesthetics. One case of plexus irritation caused by 
an interscalene catheter was reported [23]. Borgeat et al. [24] 
reported a 11% incidence of neurological complications, mostly 
minor, 10 days after CISB, which decreased to 6, 2.6, and 0.4% 
after 1, 3 and 6 months, respectively. They also reported that 
CISB does not increase the risk of nerve injury compared to 
single-shot techniques.
    The incidence of nausea and vomiting was infrequent and 
similar in both groups, and within the range of previous 
results [2]. The degree of patient satisfaction was high in the 
two groups and comparable to that reported in previous trials 
[1,2]. The high satisfaction of patients with the pain therapy in 
both groups shows the high quality of the CISB for additional 
regional anesthesia in shoulder surgery.
    In this study, there were no medical complications attribu-
table to the initial regional block, catheter placement or 
perineural infusion. However, the small number of patients 
means definite conclusions regarding its relative safety cannot 
be drawn.
    There were some limitations regarding the study protocol, 
which must be considered when interpreting this data. First, 
the subjects and investigators were not masked to the treatment 
group. The pump for CISB continuously displays the reservoir 
volume, and although not instructed on how to do this, some 
patients may have determined their basal rate using this 
information, which may have compromised the double-blinded 
nature of the study. However, it is unlikely that patients had a 
bias toward one basal infusion rate or the other. 
    Second, interscalene catheters were placed for a range of 
procedures, each expected to be associated with a different 
postoperative pain intensity, which may have limited the ability 
of the study to detect a difference in postoperative pain between 
the treatment groups.
    Third, 3 patients underwent surgery with general anesthesia. It 
is not believed that these low patients given general anesthesia 
might have influenced the results because they received similar 
doses of sufentanil and more doses of propofol to maintain 
anesthesia, the effects of which would rapidly disappear. 
    Fourth, the number of patient-controlled bolus doses admini-
stered was unavailable. The portable infusion pump described 
in this study cannot record the infusion/bolus details. This 
weakness might decrease the level of confidence in these 
results. Future studies will correct for the lack of total local 
anesthetic required in each treatment group. 
    Fifth, only pain intensity at the PACU, and 24 and 48 h after 
surgery was assessed. Breakthrough pain after resolution of the 
primary block generally occurs during 24 hours after surgery. 
Therefore, a more accurate comparison will require a shorter 
assessment interval.
    In conclusion, after shoulder surgery, CISB with 0.2% ropiva-
caine at a basal rate of 6 ml/h (3 ml bolus and 20 min lock-out 
interval) produced similar analgesia, supplemental analgesia, 
motor block, adverse events and patient’s satisfaction to that 
produced at a basal rate of 8 ml/h. Therefore, decreasing the 33 www.ekja.org
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basal rate of CISB is more appropriate considering the side 
effects of local anesthetics. However, further studies will be 
needed to determine the optimal basal infusion volumes of 
ropivacaine in CISB.
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